 Bristol Myers Squibb Co NYSE: BMY and Exelixis Inc NASDAQ: EXEL announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo nivolumab and Cabometyx cabozantinib versus sunitinib in the first-line treatment of advanced renal cell carcinoma. The updated results will be featured at the American Society of Clinical Oncology ASCO 2022 Genitourinary Cancers Symposium. 